CTOs on the Move

Mesquite Medical Assoc

www.mesquitemedical.com

 
Mesquite Medical Assoc is a Mesquite, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Turnpaugh Health and Wellness Center

Turnpaugh Health and Wellness Center is a healthcare center that takes a whole body approach to health and wellness care, incorporating physical medicine, nutrition, emotional health, and ongoing support.

Beth Israel Lahey Health

Beth Israel Lahey Health is a new, integrated system providing patients with better care wherever they are. Care informed by world-class research and education. We are doctors and nurses, technicians and social workers, innovators and educators, and so many others. All with a shared vision for what health care can and should be.

AssistMed

AssistMed is a Beverly Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Indivumed

Indivumed is a Kensington, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.